Aquavit Pharmaceuticals

Media

Aquavit Pharmaceuticals welcomes Tom Albright as its newest corporate advisory board member.

New York, NEW YORK, July 7, 2017

Aquavit Pharmaceuticals welcomes Tom Albright as its newest corporate advisory board member. Mr. Albright has over 35 years of experience in the field of pharmaceutical, biologic, device and medical aesthetics.

Mr. Albright currently serves as the CEO of Recros Medica and Chairman and CEO of Andrew Technologies. Prior to that, he was president of the topical aesthetic division at Syneron Medical, Head of North American marketing at Nobel Biocare. His medical aesthetic experience commenced with Allergan (2000 – 2008), where he led the launch of BOTOX® Cosmetic and the commercial development of Latisse®.

Mr. Albright began his career as a marketing director at Parke-Davis division of Warner Lambert, where he led the successful marketing launch of Lipotor® and many other leading brands. Since then, Mr. Albright has held various leadership positions at Allergan, Nobel Biocare, and most previously at Syneron-Candela, as the President and General Manager of the Topical Aesthetic Division.

“We are very excited to have Mr. Albright join our corporate advisory board. His extensive experience and knowledge in medical aesthetics will successfully guide our patented innovations through the fastest growing industry. He will play a key role in developing and licensing our iMicrotox program”, said Sobin Chang, CEO of Aquavit.

About Aquavit Pharmaceuticals, Inc.

Aquavit Pharmaceuticals is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies. For more information, visit www.aquavitpharma.com